Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine
Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine
复制标题
DOI：
10.1097/00002030-200307040-00021
复制
发表时间：
2003-07-04
期刊：
影响因子：
3.8
通讯作者：
Gerna, G
中科院分区：
文献类型：
--
作者：
Baldanti, F;Paolucci, S;Gerna, G
在非核苷逆转录酶抑制剂 (NNRTI) 治疗的患者中，司他夫定给药不会增加 Y181I/C 逆转录酶 (RT) 突变的频率。然而，相对于重组野生型和K103N HIV-1 株，重组Y181C HIV-1 显示出司他夫定敏感性降低。此外，与野生型和 K103N RT 相比，重组 Y181I RT 酶对司他夫定的敏感性降低。奈韦拉平或其他 NNRTI 选择的 Y181I/C RT 变化在确定司他夫定耐药性方面先前未被注意到的作用已被记录。
Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.